Spero Therapeutics
SPRO
84 hedge funds and large institutions have $317M invested in Spero Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 13 closing their positions.
54% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $711K
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
4.1% more ownership
Funds ownership: 57.14% → 61.24% (+4.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 87 → 84 (-3)
6% less capital invested
Capital invested by funds: $338M → $317M (-$21.6M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$6.36M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$935K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$661K |
| 4 |
State Street
Boston,
Massachusetts
|
+$655K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$563K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$3.55M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$2.81M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$1.07M |
| 4 |
WJWM
Williams Jones Wealth Management
New York
|
-$484K |
| 5 |
CCIA
Campbell & Co Investment Adviser
Baltimore,
Maryland
|
-$440K |
SPRO Hedge Fund Activity: Q4 2021 in Review
84 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2021, worth a combined $317M — down 6.4% from $338M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SPRO and 10 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 25 added.
The largest buyer was Aquilo Capital Management, adding an estimated $6.36M. The largest seller was BVF Inc, cutting an estimated $3.55M.
- 84 institutional investors held Spero Therapeutics (SPRO) as of Q4 2021, down from 87 in Q3 2021.
- Funds reported $317M of Spero Therapeutics stock for Q4 2021, down 6.4% quarter-over-quarter.
- 10 funds opened new Spero Therapeutics positions in Q4 2021 and 13 closed out, a net change of -3 holders.
- The largest Spero Therapeutics buyer in Q4 2021 was Aquilo Capital Management, an estimated $6.36M added.
- The largest Spero Therapeutics seller in Q4 2021 was BVF Inc, an estimated $3.55M sold.
Based on aggregated 13F filings for Q4 2021.